BTIG analyst Marie Thibault maintained a Hold rating on Abiomed (ABMD – Research Report) today. The company’s shares closed last Tuesday at $331.50.
According to TipRanks.com, Thibault is a 5-star analyst with an average return of 20.4% and a 38.5% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Edwards Lifesciences.
Abiomed has an analyst consensus of Hold, with a price target consensus of $358.75.
See the top stocks recommended by analysts >>
Based on Abiomed’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $261 million and net profit of $45.75 million. In comparison, last year the company earned revenue of $232 million and had a net profit of $61.87 million.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABMD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded in 1981 and is headquartered in Danvers, MA.
Read More on ABMD:
- Chardan Capital Thinks Pear Therapeutics’ Stock is Going to Recover
- Wells Fargo Remains a Buy on Equitable Holdings (EQH)
- AMC Vs. GameStop: Which Meme Stock Has Real Potential?
- Goldman Sachs Stock: Growth Catalysts Outshine Near-Term Woes
- Analysts Are Bullish on Top Services Stocks: Domino’s Pizza Enterprises Limited (DPZUF), Star Entertainment Group Limited (EHGRF)
